The most groundbreaking individual studies from the latest supplement and nutrition research — in plain language, with the evidence caveats built in. Research signals worth knowing about, not health advice.
This is the first meta-analysis to suggest lactoferrin may help prevent diarrhea in kids, but because the included studies were unblinded and the overall evidence is still sparse, the result should be considered preliminary.
This is the first broad synthesis to link a specific probiotic (Lactobacillus lactis LI-23) to reduced eczema in babies, but because the underlying studies were weak and the review itself is early, the finding is intriguing rather than actionable.
This is among the first systematic reviews to link fish consumption with brain structure changes, but the evidence is still early and limited to older adults, so it's a promising clue rather than a settled fact.
This is a single randomized trial on a specific Bifidobacterium breve strain, and while the effect size is striking, it hasn’t been independently replicated — treat it as a promising lead, not a settled fact.
This meta-analysis of three trials found a moderate, statistically reliable reduction in a key long-term blood sugar marker, though the effect size is modest and the picture is based on a limited number of studies.
This is among the first controlled tests of collagen on GLP-1, a hormone that signals fullness, but with only one short study in physically active women, it’s too early to say whether the effect is real or repeatable in a broader population.
This is a small pilot study, so the finding is intriguing but far from conclusive — especially since most cognitive tests in the trial came up empty.
This is the first controlled trial to show whey protein can selectively preserve lean mass after one-anastomosis gastric bypass, but the short duration and narrow patient group mean the finding needs replication before it applies broadly.
This is among the first rigorous trials on vitamin E for MASH, so the finding is promising but far from settled — especially given the serious adverse events reported and the fact that it only tested a specific Chinese clinical population.
This meta-analysis suggests that the relationship between folate and colorectal cancer risk may depend on genetics, but the finding is preliminary — it's among the first to examine this specific pairing, so replication is needed before drawing firm conclusions.
The result is promising for a specific clinical population, but with only 6 small studies and a moderate strength of evidence, it's far from a general recommendation for healthy people.
This is the first solid synthesized evidence that a compound found in raspberries can improve a key blood fat, but it's based on only three studies in a clinical population, so the finding is promising but far from settled for general use.
Because this is among the first studies to test this specific supplement–drug combo, the striking reduction in abdominal fat is promising but far from proven — especially since the benefit may depend on the metformin co-treatment and the PCOS population.
The effect is large and well-measured in a double-blind trial, but because this is one of the first studies on vitamin C for post-surgical pain, the results need replication before they can be considered reliable.
This is among the first indexed studies on anthocyanins and inflammation, so the finding is promising but requires replication; the effect also did not extend to all cholesterol markers, narrowing the benefit.
This is one of the first pooled analyses on theanine for cognition, so the finding is promising but far from settled; the moderate effect size comes with enough uncertainty that a person might notice little to no difference in real life.
This is one of the first studies to test probiotics specifically for stress in underweight adults, so the finding is intriguing but far from settled — it may not apply to people with normal weight or different gut microbiomes.
This is one of the first meta-analyses to look at vitamin D and follicle count, so the finding is intriguing but far from settled — especially since a core measure of egg supply (AMH) didn't budge.
This meta-analysis suggests curcumin may be a reasonable alternative to standard steroid treatment for oral lichen planus, but the evidence is still thin and conflicting — the study found no significant difference in clinical lesion improvement across follow-ups, and pain reduction was also not significant.
This triple-blind trial offers the first rigorous evidence that black cumin applied topically might speed healing after childbirth-related tearing, but because it’s a single study in a very specific clinical population, the result is intriguing rather than settled.
This is the first controlled trial to test saffron for sleep in Parkinson’s disease, so the result is intriguing but far from settled — one study in 92 people with a complex neurological condition cannot yet be generalized to healthy adults or other groups.
This is one of the first large meta-analyses to link selenium specifically to advanced prostate cancer, but the finding relies on observational data where selenium was measured in toenails (a long-term marker), and the studies varied so much that the result should be treated as preliminary, not definitive.
A 0.31% drop in average blood sugar over months is a modest but clinically meaningful improvement, though the finding rests on just four small studies with low overall evidence strength, so it's far from a settled recommendation.
This null finding challenges the popular belief that milk thistle reliably improves liver enzyme levels, but the evidence is too low-quality and the study too early in the research arc to call the question settled.
This analysis of six studies suggests Lactobacillus acidophilus L-92 may be a helpful add-on for pediatric atopic dermatitis, but the benefit appears limited to symptom relief, not underlying immune markers, and the overall evidence is only moderate.
This is one of the first pieces of meta-analytic evidence linking zinc to motor function in autism, but with no blinding and a single 12-week duration, it’s an early signal — not a settled recommendation.
This striking drop in interleukin-6 is promising for reducing inflammation in a clinical setting, though the broader evidence for vitamin D's anti-inflammatory effects is mixed, and the same study found no benefit for two other inflammatory markers.
This is the first meta-analysis to systematically link olive oil to diabetes risk, but with few underlying studies and a focus on European clinical populations, the result is an early signal — not a settled fact.
The result is promising but preliminary: this is among the first indexed studies to rank garlic’s antioxidant effect via a network meta-analysis, and because the participants all had MAFLD (a clinical group), the size of the effect likely doesn’t translate directly to healthy people.
This is the first controlled test of artichoke for fatty liver, and while the results are promising, a single small pilot study in a specific clinical population isn't enough to act on — especially since the same extract unexpectedly raised a marker of liver stress.